Literature DB >> 3485686

Purification to homogeneity and NH2-terminal amino acid sequence of a novel interleukin 1 species derived from a human B cell line.

L Rimsky, H Wakasugi, P Ferrara, P Robin, J Capdevielle, T Tursz, D Fradelizi, J Bertoglio.   

Abstract

A subclone, referred to as 3B6, derived from a DR-negative EBV-transformed B cell line, has been found to spontaneously produce IL 1. 3B6-IL 1 displays a pI of 5 on FPLC chromatofocusing. It has been purified to homogeneity by a sequence of ion-exchange chromatography and affinity chromatography on procion red agarose. The homogeneous material migrated with an apparent m.w. of 13,500 on SDS-PAGE. The overall recovery of IL 1 activity was estimated at 57%. The final material had a specific activity of 7.8 X 10(6) half-maximal units/mg and represented a 50,000-fold purification. A partial NH2-terminal amino acid sequence has been obtained that is different from those reported from monocytic IL 1. However, this molecule can formally be identified as IL 1 on its spectrum of biologic activities. In addition to inducing the proliferation of murine thymocytes in the co-stimulator assay. 3B6-IL 1 is active on both human T and B cells, respectively, in inducing IL 2 synthesis by cells from a subcloned HSB 2 line and promoting the proliferation of anti-IgM-stimulated human peripheral blood B lymphocytes. Furthermore, 3B6-IL 1 acts as a growth factor for normal human fibroblasts and for the 3B6 line itself. However, 3B6-IL 1 is not pyrogenic in rabbits. Thus, the 3B6 cell line was shown to produce a new molecular species of IL 1, with respect to its NH2-terminal sequence, which shared all of the studied biologic activities of monocytic IL 1 except for pyrogenicity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3485686

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

Review 1.  The role of tumor necrosis factor and interleukin 1 in the immunoinflammatory response.

Authors:  J W Larrick; S L Kunkel
Journal:  Pharm Res       Date:  1988-03       Impact factor: 4.200

2.  Epstein-Barr virus-containing B-cell line produces an interleukin 1 that it uses as a growth factor.

Authors:  H Wakasugi; L Rimsky; Y Mahe; A M Kamel; D Fradelizi; T Tursz; J Bertoglio
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

3.  Adult T-cell leukemia-derived factor/thioredoxin, produced by both human T-lymphotropic virus type I- and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2.

Authors:  N Wakasugi; Y Tagaya; H Wakasugi; A Mitsui; M Maeda; J Yodoi; T Tursz
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

4.  Epstein-Barr-virus-transformed lymphoblastoid cell lines derived from patients with X-linked agammaglobulinaemia and Wiskott-Aldrich syndrome: responses to B cell growth and differentiation factors.

Authors:  Y L Lau; J G Shields; R J Levinsky; R E Callard
Journal:  Clin Exp Immunol       Date:  1989-02       Impact factor: 4.330

5.  Induction of B cell responsiveness to growth factors by Epstein-Barr virus conversion: comparison of endogenous factors and interleukin-1.

Authors:  B A Blazar; A M Murphy
Journal:  Clin Exp Immunol       Date:  1990-04       Impact factor: 4.330

6.  Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells.

Authors:  J M Zarling; M Shoyab; H Marquardt; M B Hanson; M N Lioubin; G J Todaro
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

Review 7.  Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD.

Authors:  G Tosato; J Teruya-Feldstein; J Setsuda; S E Pike; K D Jones; E S Jaffe
Journal:  Springer Semin Immunopathol       Date:  1998

8.  Human plasma accelerates immortalization of B lymphocytes by Epstein-Barr virus.

Authors:  E Manor
Journal:  Cell Prolif       Date:  2008-04       Impact factor: 6.831

9.  Adult T-cell leukaemia-derived factor/thioredoxin expression on the HTLV-I transformed T-cell lines: heterogeneous expression in ALT-2 cells.

Authors:  S Makino; H Masutani; N Maekawa; I Konishi; S Fujii; R Yamamoto; J Yodoi
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

10.  The marmoset B-lymphoblastoid cell line (B95-8) produces and responds to B-cell growth and differentiation factors: role of shed CD23 (sCD23).

Authors:  R E Callard; Y L Lau; J G Shields; S H Smith; J Cairns; L Flores-Romo; J Gordon
Journal:  Immunology       Date:  1988-11       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.